![Helen Jones](https://profiles-cardiff.imgix.net/attachments/1081?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Helen Jones
Senior Lecturer
- JonesHE1@cardiff.ac.uk
- +44 29208 74771
- Sir Martin Evans Building, Room Cardiff School of Biosciences, The Sir Martin Evans Building, Museum Avenue, Cardiff, CF10 3AX, Museum Avenue, Cardiff, CF10 3AX
Overview
Research overview
My general interest is in the area of cell biology, specifically in the topics of cell signalling, cancer biology and programmed cell death. My speciality is the role of cell signalling in disease processes, with specific expertise regarding aberrant cell signalling mechanisms that lead to the development and progression of cancer. Such interests also encompass how cancer-related deregulated signalling can be therapeutically targeted using novel anti-cancer strategies.
Publication
2008
- Law, J. H. et al. 2008. Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Research 68(24), pp. 10238-10246. (10.1158/0008-5472.CAN-08-2755)
- Knowlden, J. M., Jones, H. E., Barrow, D., Gee, J. M. W., Nicholson, R. I. and Hutcheson, I. R. 2008. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Research and Treatment 111(1), pp. 79-91. (10.1007/s10549-007-9763-9)
- Nicholson, R. I., Hutcheson, I. R., Jones, H. E., Taylor, K. M., Hiscox, S. E. and Gee, J. M. W. 2008. Compensatory signalling induced by anti-hormone and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted therapies.. In: Pasqualini, J. R. ed. Breast cancer: prognosis, treatment and prevention. 2nd ed. London: Informa Healthcare, pp. 123-136.
2006
- Hutcheson, I. R. et al. 2006. Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocrine-Related Cancer 13(S1), pp. S89-S97. (10.1677/erc.1.01279)
- Jones, H. E., Gee, J. M. W., Hutcheson, I. R., Knowlden, J. M., Barrow, D. and Nicholson, R. I. 2006. Growth factor receptor interplay and resistance in cancer. Endocrine-Related Cancer 13(S1), pp. S45-S51. (10.1677/erc.1.01275)
- Jones, H. E., Gee, J. M. W., Barrow, D., Tonge, D., Holloway, B. and Nicholson, R. I. 2006. Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. British Journal of Cancer 95(2), pp. 172-180. (10.1038/sj.bjc.6603237)
- Jones, H. E., Gee, J. M. W., Hutcheson, I. R. and Nicholson, R. I. 2006. Growth factor pathway switching: implications for the use of gefitinib and trastuzumab. Breast Cancer Online 9(7), article number: e27. (10.1017/S1470903106005451)
- Jones, H. E., Gee, J. M. W., Barrow, D., Holloway, B., Tonge, D. and Nicholson, R. I. 2006. Maintenance of EGFR phosphorylation by the IGF-1R in the presence of gefitinib in lung cancer cells: Co-targeting the EGFR and IGF-1R maximises anti-tumour effects [Abstract]. Annals of Oncology 17(S3), pp. iii39. (10.1093/annonc/mdl919)
2005
- Gee, J. M. W. et al. 2005. Consensus statement. Endocrine-Related Cancer 12(S1), pp. S1-S7. (10.1677/erc.1.01054)
- Jones, H. E., Gee, J. M. W., Taylor, K. M., Barrow, D., Williams, H. D., Rubini, M. and Nicholson, R. I. 2005. Development of strategies for the use of anti-growth factor treatments. Endocrine-Related Cancer 12(S1), pp. S173-S182. (10.1677/erc.1.01004)
- Nicholson, R. I. et al. 2005. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. The Journal of Steroid Biochemistry and Molecular Biology 93(2-5), pp. 257-262. (10.1016/j.jsbmb.2004.12.006)
2004
- Jones, H. E. et al. 2004. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine-Related Cancer 11(4), pp. 793-814. (10.1677/erc.1.00799)
- Hutcheson, I. R., Gee, J. M. W., Barrow, D., Jones, H. E., Wakeling, A. E. and Nicholson, R. I. 2004. Treatment of tamoxifen-resistant MCF-7 breast cancer cells with either gefitinib ('Iressa') or trastuzumab (Herceptin((R))) generates cross-resistant phenotypes [Abstract]. Breast Cancer Research and Treatment 88(S1), pp. S145-S146. (10.1007/s10549-004-3602-z)
- Nicholson, R. et al. 2004. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10(1), pp. 346s-354s. (10.1158/1078-0432.CCR-031206)
- Gee, J. M. W., Gutteridge, E., Robertson, J. F., Wakeling, A. E., Jones, H. E. and Nicholson, R. I. 2004. Biological markers during early treatment of tamoxifen resistant breast cancer with gefitinib ('Iressa')[Abstract]. Breast Cancer Research and Treatment 88(S1), pp. S32. (10.1007/s10549-004-3602-z)
2003
- Jones, H. E. 2003. Escherichia coli lacking the AcrAB multidrug efflux pump also lacks nonproteinaceous, PHB-polyphosphate Ca2+ channels in the membrane. Biochimica et Biophysica Acta (BBA) - Biomembranes 1612(1), pp. 90-97. (10.1016/S0005-2736(03)00082-8)
- Knowlden, J. M. et al. 2003. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144(3), pp. 1032-1044. (10.1210/en.2002-220620)
- Nicholson, R. I. et al. 2003. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib ('Iressa', ZD1839) in MCF-7 human breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82(S1), pp. S171. (10.1023/A:1026252325164)
2002
- Nicholson, R. I. et al. 2002. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. In: Castagnetta, L. et al. eds. Hormone-Related Tumors: Novel Approaches to Prevention and Treatment. Annals of the New York Academy of Sciences Vol. 963. New York: The New York Academy of Sciences, pp. 104-115., (10.1111/j.1749-6632.2002.tb04101.x)
2001
- Nicholson, R. I. et al. 2001. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocrine-Related Cancer 8(3), pp. 175-182. (10.1677/erc.0.0080175)
- Jones, H. E., Barrow, D., Dutkowski, C., Goddard, L., Smith, C., Harper, M. E. and Nicholson, R. I. 2001. Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: Identification of divergent growth regulatory pathways. The Prostate 49(1), pp. 38-47. (10.1002/pros.1116)
2000
- Sala-Newby, G. B. et al. 2000. Targeted bioluminescent indicators in living cells. In: Ziegler, M. et al. eds. Bioluminescence and Chemiluminescence Part C., Vol. 305. Methods in Enzymology Vol. 305. San Diego, CA: Academic Press, pp. 479-498.
1999
- Holland, I. B., Jones, H. E., Campbell, A. K. and Jacq, A. 1999. An assessment of the role of intracellular free Ca2+ in E-coli. Biochimie 81(8-9), pp. 901-907. (10.1016/S0300-9084(99)00205-9)
- Jones, H. E., Holland, I. B., Baker, H. L. and Campbell, A. K. 1999. Slow changes in cytosolic free Ca2+ in Escherichia coli highlight two putative influx mechanisms in response to changes in extracellular calcium. Cell Calcium 25(3), pp. 265-274. (10.1054/ceca.1999.0028)
1997
- Jones, H. E., Eaton, C. L., Barrow, D., Dutkowski, C. M., Gee, J. M. W. and Griffiths, K. 1997. Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor-alpha and the expression of various growth factors in neoplastic and non-neoplastic prostatic cell lines. Prostate 30(4), pp. 219-231. (10.1002/(SICI)1097-0045(19970301)30:4<219::AID-PROS1>3.0.CO;2-G)
Articles
- Law, J. H. et al. 2008. Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Research 68(24), pp. 10238-10246. (10.1158/0008-5472.CAN-08-2755)
- Knowlden, J. M., Jones, H. E., Barrow, D., Gee, J. M. W., Nicholson, R. I. and Hutcheson, I. R. 2008. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Research and Treatment 111(1), pp. 79-91. (10.1007/s10549-007-9763-9)
- Hutcheson, I. R. et al. 2006. Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocrine-Related Cancer 13(S1), pp. S89-S97. (10.1677/erc.1.01279)
- Jones, H. E., Gee, J. M. W., Hutcheson, I. R., Knowlden, J. M., Barrow, D. and Nicholson, R. I. 2006. Growth factor receptor interplay and resistance in cancer. Endocrine-Related Cancer 13(S1), pp. S45-S51. (10.1677/erc.1.01275)
- Jones, H. E., Gee, J. M. W., Barrow, D., Tonge, D., Holloway, B. and Nicholson, R. I. 2006. Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. British Journal of Cancer 95(2), pp. 172-180. (10.1038/sj.bjc.6603237)
- Jones, H. E., Gee, J. M. W., Hutcheson, I. R. and Nicholson, R. I. 2006. Growth factor pathway switching: implications for the use of gefitinib and trastuzumab. Breast Cancer Online 9(7), article number: e27. (10.1017/S1470903106005451)
- Jones, H. E., Gee, J. M. W., Barrow, D., Holloway, B., Tonge, D. and Nicholson, R. I. 2006. Maintenance of EGFR phosphorylation by the IGF-1R in the presence of gefitinib in lung cancer cells: Co-targeting the EGFR and IGF-1R maximises anti-tumour effects [Abstract]. Annals of Oncology 17(S3), pp. iii39. (10.1093/annonc/mdl919)
- Gee, J. M. W. et al. 2005. Consensus statement. Endocrine-Related Cancer 12(S1), pp. S1-S7. (10.1677/erc.1.01054)
- Jones, H. E., Gee, J. M. W., Taylor, K. M., Barrow, D., Williams, H. D., Rubini, M. and Nicholson, R. I. 2005. Development of strategies for the use of anti-growth factor treatments. Endocrine-Related Cancer 12(S1), pp. S173-S182. (10.1677/erc.1.01004)
- Nicholson, R. I. et al. 2005. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. The Journal of Steroid Biochemistry and Molecular Biology 93(2-5), pp. 257-262. (10.1016/j.jsbmb.2004.12.006)
- Jones, H. E. et al. 2004. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine-Related Cancer 11(4), pp. 793-814. (10.1677/erc.1.00799)
- Hutcheson, I. R., Gee, J. M. W., Barrow, D., Jones, H. E., Wakeling, A. E. and Nicholson, R. I. 2004. Treatment of tamoxifen-resistant MCF-7 breast cancer cells with either gefitinib ('Iressa') or trastuzumab (Herceptin((R))) generates cross-resistant phenotypes [Abstract]. Breast Cancer Research and Treatment 88(S1), pp. S145-S146. (10.1007/s10549-004-3602-z)
- Nicholson, R. et al. 2004. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10(1), pp. 346s-354s. (10.1158/1078-0432.CCR-031206)
- Gee, J. M. W., Gutteridge, E., Robertson, J. F., Wakeling, A. E., Jones, H. E. and Nicholson, R. I. 2004. Biological markers during early treatment of tamoxifen resistant breast cancer with gefitinib ('Iressa')[Abstract]. Breast Cancer Research and Treatment 88(S1), pp. S32. (10.1007/s10549-004-3602-z)
- Jones, H. E. 2003. Escherichia coli lacking the AcrAB multidrug efflux pump also lacks nonproteinaceous, PHB-polyphosphate Ca2+ channels in the membrane. Biochimica et Biophysica Acta (BBA) - Biomembranes 1612(1), pp. 90-97. (10.1016/S0005-2736(03)00082-8)
- Knowlden, J. M. et al. 2003. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144(3), pp. 1032-1044. (10.1210/en.2002-220620)
- Nicholson, R. I. et al. 2003. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib ('Iressa', ZD1839) in MCF-7 human breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82(S1), pp. S171. (10.1023/A:1026252325164)
- Nicholson, R. I. et al. 2001. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocrine-Related Cancer 8(3), pp. 175-182. (10.1677/erc.0.0080175)
- Jones, H. E., Barrow, D., Dutkowski, C., Goddard, L., Smith, C., Harper, M. E. and Nicholson, R. I. 2001. Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: Identification of divergent growth regulatory pathways. The Prostate 49(1), pp. 38-47. (10.1002/pros.1116)
- Holland, I. B., Jones, H. E., Campbell, A. K. and Jacq, A. 1999. An assessment of the role of intracellular free Ca2+ in E-coli. Biochimie 81(8-9), pp. 901-907. (10.1016/S0300-9084(99)00205-9)
- Jones, H. E., Holland, I. B., Baker, H. L. and Campbell, A. K. 1999. Slow changes in cytosolic free Ca2+ in Escherichia coli highlight two putative influx mechanisms in response to changes in extracellular calcium. Cell Calcium 25(3), pp. 265-274. (10.1054/ceca.1999.0028)
- Jones, H. E., Eaton, C. L., Barrow, D., Dutkowski, C. M., Gee, J. M. W. and Griffiths, K. 1997. Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor-alpha and the expression of various growth factors in neoplastic and non-neoplastic prostatic cell lines. Prostate 30(4), pp. 219-231. (10.1002/(SICI)1097-0045(19970301)30:4<219::AID-PROS1>3.0.CO;2-G)
Book sections
- Nicholson, R. I., Hutcheson, I. R., Jones, H. E., Taylor, K. M., Hiscox, S. E. and Gee, J. M. W. 2008. Compensatory signalling induced by anti-hormone and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted therapies.. In: Pasqualini, J. R. ed. Breast cancer: prognosis, treatment and prevention. 2nd ed. London: Informa Healthcare, pp. 123-136.
- Nicholson, R. I. et al. 2002. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. In: Castagnetta, L. et al. eds. Hormone-Related Tumors: Novel Approaches to Prevention and Treatment. Annals of the New York Academy of Sciences Vol. 963. New York: The New York Academy of Sciences, pp. 104-115., (10.1111/j.1749-6632.2002.tb04101.x)
- Sala-Newby, G. B. et al. 2000. Targeted bioluminescent indicators in living cells. In: Ziegler, M. et al. eds. Bioluminescence and Chemiluminescence Part C., Vol. 305. Methods in Enzymology Vol. 305. San Diego, CA: Academic Press, pp. 479-498.
Research
My particular research interests involves the role that growth factor signalling plays in promoting the growth and development of the cancer phenotype. Indeed, over-expression and activity of growth factor receptor signalling has been associated with advanced metastatic disease and both intrinsic and acquired resistance to anti-cancer treatments. My research has been concerned with investigating the role that signalling via receptors such as the epidermal growth factor receptor and insulin-like growth factor-1 receptor contribute to the growth of breast cancer cells resistant to the breast cancer drug Tamoxifen, as resistance to this treatment is a major clinical problem.
Complementing this area, my research has also included evaluating the ability of novel signal transduction modulator (STM) drugs to target deregulated growth factor signalling in tumour cells.
Additionally, the elucidation of mechanisms underlying intrinsic and acquired resistance to STMs has also been studied in order to improve therapies and determine rational combination treatments to prevent or delay the emergence of the resistant tumour phenotype.
Teaching
Year 2 Medicine Student Selected Component Co-ordinator
Biography
After gaining a degree in Biomedical Sciences, I undertook my Ph.D. in Cell Biology in the Department of Zoology at Cardiff University, where I investigated the role of programmed cell death occurring during the metamorphosis of Drosophila melanogaster.
Several postdoctoral positions later, which encompassed the areas of toxicology, prostate cancer and cell imaging, I returned to the field of cancer research, gaining an AstraZeneca funded position in the Tenovus Centre for Cancer Research in the Welsh School of Pharmacy in Cardiff University. This position lasted 7 years, where I elucidated the mechanisms of de novo and acquired resistance to novel 'intelligent' anticancer therapies which target growth factor receptors and their signalling transduction cascades.
I subsequently joined the School of Biosciences as a Professional Tutor and I am extending my areas of interest into pedagogic topics. To this end, I have recently become a Fellow of the Higher Education Academy.